Tag: Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety

PN6047

PharmNovo’s CTA submission for lead candidate PN6047

HTP Desk - 0
PN6047 is a first-in-class small molecule that selectively activates the delta opioid receptor (DOR), avoiding interaction with the mu opioid receptor that is the...